Rivaroxaban plus aspirin after lower-extremity revascularization

Introduction Patients undergoing revascularization of the lower extremities have unacceptably high rates of major adverse cardiac and limb events despite the routine use of antiplatelet therapy. Optimization of antithrombotic therapy provides an opportunity to reduce this risk. Recent large, randomized trials have demonstrated substantial benefit from the combination of low dose rivaroxaban and aspirin compared with aspirin alone. Despite this new evidence, uptake remains limited.